london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Management of macular edema and/or macular detachment secondary to retinal artery macroaneurysms

Poster Details

First Author: S.W.Choi SOUTH KOREA

Co Author(s):    K.H. Hong   Y.C. Kim   K.S. Kim            0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To evaluate the efficacy of various treatment modality of macular edema(ME) and/or macular detachment associated with retinal artery macroaneurysm(RAM).

Setting:

Retrospective interventional, randomized study

Methods:

The study included 17 patients (17 eyes) with symptomatic RAM. All patients underwent a comprehensive ophthalmic examination, fluorescein angiography(FA), and spectral-domain optical coherence tomography(SD OCT). Ruptured and acute hemorrhagic type RAM involving macula were excluded. They were received intravitreal bevacizumab injection(IVB) in 8 eyes, focal laser photocoagulation(FLP) in 4 eyes and combined IVB and FLP in 2 eyes as a first treatment method. Three eyes were just observed due to relatively good initial visual acuity(VA) and mild ME. Each patients followed as-needed and determined further treatment. Mean best-corrected visual acuity (BCVA) and average central macular thickness (CMT) were documented and analyzed between each treatment modality. Statistical analyses were performed using SPSS software version 18.0(SPSS® Inc., Chicago, IL, USA). A P value of <.05 was considered statistically significant.

Results:

The mean follow-up period was 14.18 ± 15.3 months. The mean age was 70.24±9.35 years. Ten of 17 patients were medication for hypertension and 13 patients were women. The mean distance from fovea to aneurysm was 1.82±0.75 disc diameter(DD). The mean BCVA and CMT of all subjects at baseline were 0.54±0.41 logMAR units, 346.44±164.17 and improved at the last follow-up by 0.42±0.44 logMAR units (p=0.008), 200.07±52.62 (p=0.002). In 3 of 8 eyes, IVB-treated patients, BCVA improved and CMT decreased with initial treatment, however 5 of 8 eyes did not show any improvement even though additional treatment. They were improved after vitrectomy with 1 DD sized-sectal removal of internal limiting membrane (ILM) around RAM lesion sparing macular ILM. The mean number of injection was 1.57±0.79 and mean period to decide vitrectomy was 55.2±15.83 days after last injection. Among 4 patients treated with FLP, 2 eyes showed improvement with initial treatment, but another two eyes were improved after additional IVB. Two eyes treated with combination were improved without recurrence and 3 observed eyes showed gradual improvement over time. According to the follow-up OCT, the photoreceptor disruption patients presented a lower BCVA than that of photoreceptor preservation patients (logMAR 0.19±0.18 vs. 0.28±0.28, p=0.003).

Conclusions:

Inravitreal bevacizumab, laser photocoagulation or combination treatment could be effective treatment option for ME and/or macular detachment secondary to RAM. In follow-up period, if ME and subretinal fluid were exacervated or slow resolution over more than 2 months even though various treatment modalities, vitrectomy with sectal removal of the ILM confined to RAM lesion should be considered for photoreceptor preservation and better visual outcome.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy